This title reviews current knowledge of the mechanisms contributing to heart failure. Editor Richard Walsh and an internationally renowned team of contributors discuss key advances in molecular and cell biology, biochemistry, and pharmacology, focusing on advances that have a direct bearing on current clinical studies. It highlights developments across a broad range of disciplines, with in-depth coverage of each topic providing background and perspective on current literature. By setting new advances in a broader context, this text allows readers to compare different ideas and evaluate their importance in their own areas of research or clinical practice.

Unique in its focus on this particular field of cardiovascular science, Molecular Mechanisms of Cardiac Hypertrophy and Failure reviews current knowledge of the mechanisms contributing to heart failure.Bringing together an internationally renowned team of contributors, the text provides expert reviews on the latest advances in molecular and cell biology, biochemistry and pharmacology. scientists in academia and industry, the book has particular emphasis on the following key areas: - cardiac hypertrophy - contractile depression - arrhythmogenesis - genetics - the clinical implications of the research in these areas. interest to clinical cardiologists, vascular medicine specialists, hematologists, and internists, as well as members of the cardiovascular research community and pharmaceutical and biotechnology industries.

The enormous advances in molecular biology and genetics coupled with the progress in instrumentation and surgical techniques have produced a voluminous and often bewildering quantity of data. The primary objective of a second edition of Cardiovascular Physiology in the Genetically Engineered Mouse is to interpret critically the literature and to provide a framework for the enormous amount of information in this burgeoning field. As in the first edition, the monograph serves as a practical guide for the investigator interested in the functional methods used to characterize the murine cardiovascular phenotype. The monograph is organized into three parts. The first deals with principles of transgenesis and homologous recombination. The second part, which again is the largest, discusses the various techniques used to assess the cardiovascular mechanical, metabolic, and electrophysiologic phenotype. This section is organized in a hierarchical manner- i.e. from isolated myocyte to isolated heart to the intact, anesthetized and conscious mouse.The third part examines techniques used to evaluate murine smooth muscle function, genetic mouse models of hypertrophy and heart failure, and the methods to assess the cardiovascular phenotype in the developing mouse embryo. In addition, newer methods that 'push the envelope', such as magnetic resonance imaging (MRI), positron emission tomography (PET), ultrasound biomicroscopy (UBM), and computed tomography (microCT) are discussed. Expanded and updated, each chapter is richly enhanced with original tables and figures, and in many cases, extensively rewritten when compared with the first edition. An essential and enduring goal of this second edition is to continue to facilitate interactions between the basic science disciplines and help bridge the gap between molecular biology and physiology.

The enormous advances in molecular biology and genetics coupled with the progress in instrumentation and surgical techniques have produced a voluminous and often bewildering quantity of data. The primary objective of a second edition of Cardiovascular Physiology in the Genetically Engineered Mouse is to interpret critically the literature and to provide a framework for the enormous amount of information in this burgeoning field. As in the first edition, the monograph serves as a practical guide for the investigator interested in the functional methods used to characterize the murine cardiovascular phenotype. The monograph is organized into three parts. The first deals with principles of transgenesis and homologous recombination. The second part, which again is the largest, discusses the various techniques used to assess the cardiovascular mechanical, metabolic, and electrophysiologic phenotype. This section is organized in a hierarchical manner- i.e. from isolated myocyte to isolated heart to the intact, anesthetized and conscious mouse. The third part examines techniques used to evaluate murine smooth muscle function, genetic mouse models of hypertrophy and heart failure, and the methods to assess the cardiovascular phenotype in the developing mouse embryo. In addition, newer methods that push the envelope', such as magnetic resonance imaging (MRI), positron emission tomography (PET), ultrasound biomicroscopy (UBM), and computed tomography (microCT) are discussed. Expanded and updated, each chapter is richly enhanced with original tables and figures, and in many cases, extensively rewritten when compared with the first edition. An essential and enduring goal of this second edition isto continue to facilitate interactions between the basic science disciplines and help bridge the gap between molecular biology and physiology.

Part of the "What Do I Do Now?" series, Movement Disorders uses a case-based approach to cover common and important topics in the examination, investigation, and management of Parkinson's disease, gait disorders, dystonia, and other movement disorders. Each chapter provides a discussion of the diagnosis, key points to remember, and selected references for further reading. For this edition, all cases and references have been updated and fifteen new cases have been added including: Genetic testing in Parkinson's disease, Dementia with Lewy Bodies, Fragile X Tremor Ataxia Syndrome, Botulinum Toxin, Catatonia, and Serotonin Syndrome. Movement Disorders is an engaging collection of thought-provoking cases which clinicians can utilize when they encounter difficult patients. The volume is also a self-assessment tool that tests the reader's ability to answer the question, "What do I do now?"